TGA gives nod to non-vax COVID-19 prophylactic
The treatment combines two long-acting monoclonal antibodies and is for patients who don't respond to vaccines
The TGA has provisionally approved Australia’s first prophylactic antibody treatment for COVID-19.
Tixagevimab-cilgavimab (Evusheld) is indicated for patients aged 12 or older who may not adequately respond to COVID-19 vaccination, such as patients with haematological cancer.
According to the therapy’s makers, AstraZeneca, around 2% of patients are at risk of inadequately responding to any COVID-19 vaccination.
The therapy involves two drugs, both long-acting monoclonal antibodies, which are injected sequentially and can be repeated every six months to maintain protection.
